Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

NCT03785067 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Contractual and financial issues.

Conditions

Cognitive Decline
Intracerebral Hemorrhage
Dementia, Vascular
Cerebral Small Vessel Diseases
Hypertension
Stroke Hemorrhagic

Interventions

DRUG: telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg
DRUG: Placebo oral capsule

Sponsor

The George Institute

Collaborators

[object Object]